343,421 Shares in AVROBIO, Inc. (NASDAQ:AVRO) Bought by Gabelli Funds LLC

Gabelli Funds LLC bought a new position in shares of AVROBIO, Inc. (NASDAQ:AVROFree Report) in the fourth quarter, HoldingsChannel reports. The fund bought 343,421 shares of the company’s stock, valued at approximately $467,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of AVRO. Aldebaran Capital LLC purchased a new stake in AVROBIO in the third quarter valued at $724,000. Newtyn Management LLC purchased a new stake in AVROBIO in the third quarter valued at $3,080,000. Terrapin Asset Management LLC purchased a new stake in AVROBIO in the third quarter valued at $861,000. Affinity Asset Advisors LLC purchased a new stake in AVROBIO in the third quarter valued at $770,000. Finally, FNY Investment Advisers LLC lifted its position in AVROBIO by 77.8% in the fourth quarter. FNY Investment Advisers LLC now owns 400,000 shares of the company’s stock valued at $544,000 after acquiring an additional 175,000 shares during the last quarter. Institutional investors and hedge funds own 62.63% of the company’s stock.

Insider Activity

In other AVROBIO news, major shareholder Braden Michael Leonard bought 469,753 shares of AVROBIO stock in a transaction dated Monday, May 13th. The stock was acquired at an average cost of $1.25 per share, with a total value of $587,191.25. Following the completion of the acquisition, the insider now owns 4,471,380 shares of the company’s stock, valued at $5,589,225. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 9.20% of the company’s stock.

AVROBIO Price Performance

Shares of AVRO opened at $1.48 on Tuesday. AVROBIO, Inc. has a 1-year low of $0.88 and a 1-year high of $1.65. The stock has a market cap of $66.44 million, a PE ratio of 2.14 and a beta of 1.23. The firm has a fifty day moving average price of $1.32 and a 200 day moving average price of $1.32.

AVROBIO (NASDAQ:AVROGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share for the quarter. As a group, equities analysts expect that AVROBIO, Inc. will post -0.48 EPS for the current fiscal year.

About AVROBIO

(Free Report)

AVROBIO, Inc, a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.

See Also

Want to see what other hedge funds are holding AVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AVROBIO, Inc. (NASDAQ:AVROFree Report).

Institutional Ownership by Quarter for AVROBIO (NASDAQ:AVRO)

Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.